

Prednicortone 20 mg tablets for dogs and cats

Authorised

- Prednisolone

Product identification

Medicine name:

Prednicortone 20 mg tablets for dogs and cats

Active substance:

Prednisolone

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Prednisolone

20.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QH02AB06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Lithuania

Package description:

Cardboard box of 50 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 5 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 4 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 3 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 25 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 2 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 15 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 10 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 7 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 1 Aluminium - PVC/PE/PVDC blister of 10 tablets.
Cardboard box of 9 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 6 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
Cardboard box of 8 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Dechra Regulatory B.V.

Marketing authorisation date:

27/07/2015

Manufacturing sites for batch release:

Lelypharma B.V.
Genera d.d.

Responsible authority:

State Food And Veterinary Service

Authorisation number:

LT/2/15/2299/001-013

Date of authorisation status change:

16/08/2020

Reference member state:

Netherlands

Procedure number:

NL/V/0190/002

Concerned member states:

Austria Belgium Croatia Cyprus Czechia Denmark Estonia Finland France
Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

RV2299.pdf